RT002

RT002 is a preclinical-stage repurposed drug being developed by Revio Therapeutics for oncology indications. The program involves pivoting an existing, approved drug toward a new therapeutic application in cancer, utilizing a hydrogel-based implant formulation for local delivery. This delivery method is designed to provide targeted, sustained release of the active ingredient directly to the tumor site, potentially improving efficacy and reducing systemic toxicity. While the specific active ingredient and molecular target have not been publicly disclosed by Revio Therapeutics, the program is part of their core strategy of enhancing proven drugs through optimized delivery and new disease applications.